Imugene Ltd (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $2.28 billion
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 5.48 billion
Earnings per share -0.004
Dividend per share N/A
Year To Date Return 320.00%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Imugene Ltd (ASX: IMU)
Latest News

IMU ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Imugene Ltd

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

IMU Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
18 Oct 2021 $0.42 $-0.01 -2.38% 9,184,325 $0.43 $0.43 $0.42
15 Oct 2021 $0.42 $0.01 2.44% 7,050,268 $0.42 $0.43 $0.41
14 Oct 2021 $0.41 $0.02 5.06% 8,957,089 $0.40 $0.42 $0.40
13 Oct 2021 $0.40 $-0.03 -7.14% 11,540,191 $0.42 $0.42 $0.39
12 Oct 2021 $0.42 $0.00 0.00% 22,839,260 $0.40 $0.43 $0.40
11 Oct 2021 $0.42 $-0.03 -6.74% 10,102,411 $0.44 $0.44 $0.42
08 Oct 2021 $0.45 $-0.01 -2.22% 13,498,178 $0.46 $0.47 $0.44
07 Oct 2021 $0.45 $0.04 9.76% 20,159,495 $0.41 $0.45 $0.41
06 Oct 2021 $0.41 $-0.01 -2.38% 26,003,426 $0.42 $0.43 $0.40
05 Oct 2021 $0.42 $-0.03 -6.74% 32,929,755 $0.44 $0.44 $0.41
04 Oct 2021 $0.45 $-0.03 -6.32% 22,018,032 $0.47 $0.48 $0.45
01 Oct 2021 $0.48 $-0.01 -2.08% 15,947,527 $0.48 $0.48 $0.46
30 Sep 2021 $0.48 $0.00 0.00% 14,784,703 $0.48 $0.49 $0.47
29 Sep 2021 $0.48 $0.00 0.00% 15,411,343 $0.46 $0.48 $0.46
28 Sep 2021 $0.48 $-0.01 -2.04% 23,978,058 $0.50 $0.50 $0.46
27 Sep 2021 $0.49 $0.01 2.08% 17,203,269 $0.49 $0.51 $0.49
24 Sep 2021 $0.48 $-0.02 -4.04% 31,324,824 $0.50 $0.52 $0.48
23 Sep 2021 $0.50 $0.03 6.38% 46,027,093 $0.48 $0.50 $0.46
22 Sep 2021 $0.47 $0.02 4.40% 37,936,756 $0.47 $0.49 $0.46
21 Sep 2021 $0.46 $-0.01 -2.15% 22,858,925 $0.45 $0.47 $0.45
20 Sep 2021 $0.47 $0.00 0.00% 33,652,450 $0.46 $0.47 $0.44

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
06 Oct 2021 Lesley Russell Sell 3 $1,360,000
On-market trade.
09 Sep 2021 Paul Hopper Issued 1 $17,205
Issue of securities.
09 Sep 2021 Paul Hopper Issued 88 $1,373,624
Issue of securities.
01 Jul 2021 Lesley Russell Buy 15 $630,000
Exercise of options.
01 Jul 2021 Lesley Russell Exercise 15 $630,000
Exercise of options.
01 Jul 2021 Lesley Russell Sell 1 $629,080
On-market trade.
28 May 2021 Leslie (Mi Ok) Chong Exercise 13 $623,000
Exercise of options.
28 May 2021 Leslie (Mi Ok) Chong Buy 13 $623,000
Exercise of options.
26 May 2021 Paul Hopper Sell 1 $702,339
On-market trade.
26 May 2021 Paul Hopper Exercise 25 $1,125,000
Exercise of options.
26 May 2021 Paul Hopper Buy 25 $1,125,000
Exercise of options.
25 May 2021 Leslie (Mi Ok) Chong Sell 4 $1,648,431
On-market trade.
25 May 2021 Leslie (Mi Ok) Chong Exercise 36 $1,627,000
Exercise of options.
25 May 2021 Leslie (Mi Ok) Chong Buy 36 $1,627,000
Exercise of options.
21 May 2021 Charles Walker Sell 3 $1,236,500
On-market trade.
22 Dec 2020 Leslie (Mi Ok) Chong Exercise 98 $3,950
Exercise of options.
22 Dec 2020 Leslie (Mi Ok) Chong Buy 98 $3,950
Exercise of options.
22 Dec 2020 Paul Hopper Exercise 827 $33,091
Exercise of options.
22 Dec 2020 Paul Hopper Buy 827 $33,091
Exercise of options.
16 Dec 2020 Axel Hoos Exercise 15 $620,000
Exercise of options.
16 Dec 2020 Axel Hoos Buy 15 $620,000
Exercise of options.
11 Dec 2020 Axel Hoos Sell 3 $345,300
On-market trade.
01 Dec 2020 Charles Walker Buy 325 $8,450
Exercise of options.
01 Dec 2020 Charles Walker Exercise 123 $4,938
Exercise of options.
01 Dec 2020 Charles Walker Buy 49 $1,287
Exercise of options.
01 Dec 2020 Charles Walker Exercise 49 $1,287
Exercise of options.
01 Dec 2020 Charles Walker Exercise 325 $8,450
Exercise of options.
01 Dec 2020 Charles Walker Buy 123 $4,938
Exercise of options.
01 Dec 2020 Charles Walker Sell 7 $952,500
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Leslie (Mi Ok) Chong Chief Executive OfficerManaging Director Nov 2016
Ms Chong joined the group in September 2015 from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 23 years' experience in leading clinical and department development in oncology. In November 2016, Ms Chong was promoted as Imugene's CEO and joined the board as Managing Director in March 2018. Her other current directorships are Chimeric Therapeutics (ASX: CHM), since 28 August 2020 Cure Brain Cancer Foundation (non-profit organisation), since April 2020
Mr Paul Alex Hopper Executive ChairmanExecutive Director Dec 2013
Mr Hopper has over 20 years' experience in the management and funding of biotechnology and healthcare public companies both as Chief Executive Officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with a particular emphasis on immunotherapy and cancer vaccines. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. Other current directorships held by him are at Radiopharm Theranostics Limited, since 11 February 2021 Chimeric Therapeutics Limited (ASX: CHM), since 2 February 2020 Scopus BioPharma Inc (New York) [Stat3 technology] (NASDAQ: SCPS), since December 2020 SUDA Pharmaceuticals Ltd (ASX: SUD), since 15 May 2019
Mr Charles Walker Non-Executive Director Jan 2015
Mr Walker has experience across the biotechnology and life sciences industry. His experience includes operational and leadership positions in biotechnology firms, a strong capital markets track record from executing nearly 60 international and domestic corporate transactions, both as principal and advisor, and a detailed scientific understanding gained from a technical background in pharmacology. Mr Walker was previously Chief Executive Officer and Chief Financial Officer of Alchemia Limited (ASX: ACL) and Managing Director of Imugene.
Dr Axel Hoos Non-Executive Director Dec 2013
Dr Hoos is the CEO of Scorpion Therapeutics. Formerly, he was the Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). At GSK he led technical and funding decisions in R&D as well as Discovery and Development in Oncology with focus on immunooncology, epigenetics, cell therapy, and synthetic lethality. Dr Hoos also serves as a member of the Board of Trustees of the Sabin Vaccine Institute (SVI), a global health organization, Director on the Board of TCR2, a cell therapy company, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). Previously, Dr Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first checkpoint inhibitor in Immuno-Oncology. Before BMS, Dr Hoos was Senior Director of Clinical Development at Agenus Bio (former Antigenics). Other current directorships of his are at TCR2 Therapeutics Inc (NASDAQ: TCRR)
Dr Lesley Russell Non-Executive Director Apr 2019
Dr Russell is a haematologist/oncologist and has over 25 years' experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had multiple new drug approvals with both Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Other current directorships held by her are Chimeric Therapeutics Limited (ASX: CHM), since 28 August 2020 Enanta Pharmaceuticals (NASDAQ: ENTA), since 22 November 2016 Former directorships in last 3 years held by her are Scopus BioPharma Inc (New York) [Stat3 technology] (NASDAQ: SCPS), until March 2021 AMAG Pharma (NASDAQ: AMAG), until May 2019 Endocyte Pharmaceuticals (NASDAQ: ECYT), until December 2018
Dr Jens Eckstein Non-Executive Director May 2019
Dr Eckstein has more than 15 years' venture capital experience in the biopharmaceutical industry and 10 years' operational experience in drug discovery and development. He is a Kauffman Fellow and a mentor for lifescience entrepreneurs and start-up teams in the area of innovative lifescience and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital (APVC). Previously, he was a general partner at TVM Capital. Other current directorships held by him are Aeovian Pharmaceuticals (USA, private) Samsara Therapeutics (UK, private) Cleara Biotech (The Netherlands, private) HAYA Therapeutics (Switzerland, private) BosWell (USA, private) Former directorships in last 3 years held by him are Gladius Pharmaceuticals (Canada, private) Decibel Therapeutics (NASDAQ:DBTX) Palleon Pharmaceuticals (USA, private) ZappRx (USA, private)
Mr Phillip Hains Chief Financial OfficerJoint Company Secretary Dec 2012
-
Mr Justyn Peter Stedwell Company Secretary
-
Phillip Hains Chief Financial OfficerJoint Company Secretary
-
Dr Rita Laeufle Chief Medical Officer
-
Dr Nicholas Ede Chief Technology Officer
-
Justyn Peter Stedwell Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
No shareholder information disclosed 0 0.00%

Profile

since

Note